Диссертация (1174280), страница 21
Текст из файла (страница 21)
Trindadeet al.//Jornal Brasileiro de Pneumologia. – 2008. – Т. 34. – №. 5. – С. 333-336.110. Miralles, F. Modelling the response to low-frequency repetitive nervestimulation of myasthenia gravis and Lambert–Eaton myasthenic syndrome / F.Miralles.//Medical & biological engineering & computing. – 2016.
– Т. 54. – №.11. – С. 1761-1778.111. Monstad, S. E. Hu and voltage-gated calcium channel (VGCC) antibodiesrelated to the prognosis of small-cell lung cancer / S.E. Monstad, L. Drivsholm, A.Storstein et al.//Journal of clinical oncology. – 2004. – Т. 22. – №. 5. – С. 795-800.112. Monteiro, C. Lambert–Eaton myasthenic syndrome and prostaticadenocarcinoma / C. Monteiro, I. Moreira, J.L.
Lima et al.//Neurological Sciences.– 2015. – Т. 36. – №. 11. – С. 2145-2146.113. Morimoto, M. Thymoma with Lambert-Eaton myasthenic syndrome /M.Morimoto, T. Osaki, Y. Nagara et al.//The Annals of thoracic surgery. – 2010. – Т.89. – №. 6. – С. 2001-2003.114. Morris, C. S. Immunocytochemical characteristics of small cell lungcarcinoma associated with the Lambert-Eaton myasthenic syndrome / C.S. Morris,M.M. Esiri, A.
Marx et al.//The American journal of pathology. – 1992. – Т. 140. –№. 4. – С. 839.115. Motomura, M. An improved diagnostic assay for Lambert-Eaton myasthenicsyndrome / M. Motomura, I. Johnston, B. Lang et al.//Journal of Neurology,Neurosurgery & Psychiatry. – 1995. – Т. 58. – №. 1. – С. 85-87.138116.
Motomura, M. Incidence of serum anti-P/Q-type and anti-N-type calciumchannel autoantibodies in the Lambert-Eaton myasthenic syndrome / M.Motomura, B. Lang, I. Johnston et al.//Journal of the neurological sciences. – 1997.– Т. 147. – №. 1. – С. 35-42.117. Murray, N. M. The Lambert-Eaton myasthenic syndrome: a review of 50cases / N.M. Murray, J.H. O'neill, J.
Newsom-Davis.//Brain. – 1988. – Т. 111. –№. 3. – С. 577-596.118. Nakao, Y. K. Seronegative Lambert-Eaton myasthenic syndrome: study of110 Japanese patients /Y.K. Nakao, M. Motomura, T. Fukudome et al.//Neurology.– 2002. – Т. 59. – №. 11. – С. 1773-1775.119. Nakao, Y. K. Specificity of ω-conotoxin MVIIC-binding and-blockingcalcium channel antibodies in Lambert-Eaton myasthenic syndrome /Y.K. Nakao,M.
Motomura, A. Suenaga et al.//Journal of neurology. – 1999. – Т. 246. – №. 1. –С. 38-44.120. Nalbantoglu, M. Lambert–Eaton myasthenic syndrome associated withthymic neuroendocrine carcinoma / M. Nalbantoglu, L. Kose, N. Uzun etal.//Muscle & nerve. – 2015. – Т. 51.
– №. 6. – С. 936-938.121. Newsom-Davis, J. Lambert-Eaton myasthenic syndrome /J. NewsomDavis.//Revue neurologique. – 2004. – Т. 160. – №. 2. – С. 177-180.122. O'neill, J. H. The Lambert-Eaton myasthenic syndrome: a review of 50 cases /J.H. O'neill, N.M.F. Murray, J. Newsom-Davis.//Brain.
– 1988. – Т. 111. – №. 3. –С. 577-596.123. Odabasi, Z. Postexercise facilitation of reflexes is not common in Lambert–Eaton myasthenic syndrome /Z. Odabasi, M. Demirci, D.S. Kim et al.//Neurology.– 2002. – Т. 59. – №. 7. – С. 1085-1087.124. Oh, S. J. Electromyography: neuromuscular transmission studies / S.J. Oh. –Williams & Wilkins, 1988.125. Oh, S. J. Peroneal nerve repetitive nerve stimulation test: its value indiagnosis of myasthenia gravis and Lambert–Eaton myasthenic syndrome / S.J.Oh, T. Head, J.
Fesenmeier et al.//Muscle & Nerve: Official Journal of theAmerican Association of Electrodiagnostic Medicine. – 1995. – Т. 18. – №. 8. – С.867-873.139126. Oh, S. J. Clinical electromyography: nerve conduction studies /S.J. Oh. –Lippincott Williams & Wilkins, 2003.127. Oh, S. J. Electrophysiological diagnostic criteria of Lambert–Eatonmyasthenic syndrome / S.J. Oh, K. Kurokawa, G.C.
Claussen et al.//Muscle &Nerve: Official Journal of the American Association of ElectrodiagnosticMedicine. – 2005. – Т. 32. – №. 4. – С. 515-520.128. Oh, S. J. Electrophysiological differences in seropositive and seronegativeLambert–Eaton myasthenic syndrome / S.J. Oh, Y. Hatanaka, G.C. Claussen etal.//Muscle & nerve. – 2007. – Т. 35.
– №. 2. – С. 178-183.129. Oh, S. J. Myasthenia gravis Lambert‐Eaton overlap syndrome / S.J. Oh.//Muscle & nerve. – 2016. – Т. 53. – №. 1. – С. 20-26.130. Oh, S. J. Distinguishing Features of the Repetitive Nerve Stimulation TestBetween Lambert–Eaton Myasthenic Syndrome and Myasthenia Gravis, 50-YearReappraisal / S.J.
Oh.//Journal of clinical neuromuscular disease. – 2017. – Т. 19. –№. 2. – С. 66-75.131. Oh, S. J. MG and LEMS overlap syndrome: case report withelectrophysiological and immunological evidence /S.J. Oh, E. Sher.//Clinicalneurophysiology. – 2005. – Т. 116. – №. 5. – С. 1167-1171.132. Parkin, D. M. Global cancer statistics, 2002 /D.M. Parkin, F. Bray, J. Ferlayet al.//CA: a cancer journal for clinicians. – 2005. – Т. 55. – №. 2. – С. 74-108.133. Payne, M. Prospective study into the incidence of Lambert Eaton myasthenicsyndrome in small cell lung cancer /M.
Payne, P. Bradbury, B. Lang et al.//Journalof Thoracic Oncology. – 2010. – Т. 5. – №. 1. – С. 34-38.134. Pellkofer, H. L. Lambert–Eaton myasthenic syndrome differential reactivityof tumor versus non-tumor patients to subunits of the voltage-gated calciumchannel / H.L. Pellkofer, L. Armbruster, M. Krumbholz et al. //Journal ofneuroimmunology. – 2008. – Т. 204. – №. 1-2. – С. 136-139.135. Pellkofer, H.
L. Managing non-paraneoplastic Lambert–Eaton myasthenicsyndrome: Clinical characteristics in 25 German patients /H.L. Pellkofer, L.Armbruster, R. Linke et al.//Journal of neuroimmunology. – 2009. – Т. 217. – №.1-2. – С. 90-94.140136. Preston, D.C. Generalized myasthenia gravis: Classification, clinicalpresentation, natural history, and epidemiology / D.C. Preston, M.K. Hehir, N.J.Silvestri.//Neurologic clinics. – 2018. – Т. 36. – №. 2. – С.
253-260.137. Preston, D. C. Electromyography and Neuromuscular Disorders E-Book:Clinical-Electrophysiologic Correlations (Expert Consult-Online and Print)/ D.C.Preston, B.E. Shapiro. – Elsevier Health Sciences, 2012.138. Punga, A. R. Monozygous twins with neuromuscular transmission defects atopposite sides of the motor endplate /A.R.
Punga, I. Nygren, H. Askmark etal.//Acta Neurologica Scandinavica. – 2009. – Т. 119. – №. 3. – С. 207-211.139. Quartel, A. Current therapy for Lambert–Eaton myasthenic syndrome:development of 3, 4-diaminopyridine phosphate salt as first-line symptomatictreatment /A. Quartel, S. Turbeville, D. Lounsbury.//Current medical research andopinion. – 2010.
– Т. 26. – №. 6. – С. 1363-1375.140. Rahamimoff, R. Intracellular and extracellular calcium ions in transmitterrelease at the neuromuscular synapse /R. Rahamimoff, S.D. Erulkar, A. Lev-Tov etal.//Annals of the New York Academy of Sciences. – 1978. – Т. 307. – С. 583-598.141. Roberts, A. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux ina human small cell carcinoma line /A. Roberts, S. Perera, B. Lang et al.//Nature. –1985. – Т. 317.
– №. 6039. – С. 737.142. Romics, L. Unusual paraneoplastic syndromes of breast carcinoma: acombination of cerebellar degeneration and Lambert–Eaton Myasthenic Syndrome/L. Romics, B. McNamara, P.A. Cronin et al.//Irish journal of medical science. –2011. – Т.
180. – №. 2. – С. 569-571.143. Rudnicki, S. A. Lambert-Eaton myasthenic syndrome with pure ocularweakness /S.A. Rudnicki.//Neurology. – 2007. – Т. 68. – №. 21. – С. 1863-1864.144. Sabater, L. SOX1 antibodies are markers of paraneoplastic Lambert–Eatonmyasthenic syndrome /L. Sabater, M. Titulaer, A. Saiz et al.//Neurology. – 2008. –Т. 70. – №. 12.
– С. 924-928.145. Sabater, L. Antibody repertoire in paraneoplastic cerebellar degeneration andsmall cell lung cancer /L. Sabater, R. Höftberger, A. Boronat et al.//PLoS One. –2013. – Т. 8. – №. 3. – С. e60438.141146. Sanders, D. B. Is the decremental pattern in Lambert–Eaton syndromedifferent from that in myasthenia gravis? /D.B. Sanders, L.
Cao, J.M. Massey etal.//Clinical Neurophysiology. – 2014. – Т. 125. – №. 6. – С. 1274-1277.147. Sanders, D. B. MuSK-antibody positive myasthenia gravis: clinical andelectrodiagnostic patterns / D.B. Sanders, J.M. Massey, D.E. Stickler.//Clinicalneurophysiology. – 2005. – Т. 116. – №. 9. – С. 2065-2068.148. Sanders, D. B. Myasthenia gravis and Lambert-Eaton myasthenic syndrome /D.B. Sanders, J.T. Guptill. - CONTINUUM: Lifelong Learning in Neurology.
–2014. – Т. 20. – №. 5. – С. 1413-1425.149. Sanders, D. B. Autoimmune myasthenia gravis: emerging clinical andbiological heterogeneity / D.B. Sanders, M.N. Meriggioli.//The Lancet Neurology.– 2009. – Т. 8. – №. 5. – С. 475-490.150. Sanders, D. B. The Lambert–Eaton myasthenic syndrome / D.B. Sanders,V.C. Juel. - Handbook of clinical neurology. – 2008.
– Т. 91. – С. 273-283.151. Schoser, B. Lambert–Eaton myasthenic syndrome (LEMS): a rareautoimmune presynaptic disorder often associated with cancer /B. Schoser, B.Eymard, J. Datt et al.//Journal of neurology. – 2017. – Т. 264. – №. 9. – С. 18541863.152.
Sher, E. Nicotinic Receptors and Calcium Channels in Small Cell LungCarcinoma: Functional Role, Modulation, and Autoimmunity /E. Sher, A.Codignola, M. Passafaro et al.//Annals of the New York Academy of Sciences. –1998. – Т. 841. – №. 1. – С. 606-624.153. Simmons, D.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
